



Cite this: *RSC Chem. Biol.*, 2022, 3, 32

Received 17th September 2021,
Accepted 9th October 2021

DOI: 10.1039/d1cb00183c

rsc.li/rsc-chembio

Stapling proteins in the RELA complex inhibits TNF α -induced nuclear translocation of RELA \dagger

Smit Kour,^{‡,§} Sandeep Rana,^{‡,§,¶} Smitha Kizhake,[‡] Dragana Lagundžin,^{‡,ab} David Klinkebiel,^c Jayapal Reddy Mallareddy,^a Tom Huxford,^{ID, d} Nicholas T. Woods^{ae} and Amarnath Natarajan^{ID, *aef}

Tumor necrosis factor (TNF) α -induced nuclear translocation of the NF- κ B subunit RELA has been implicated in several pathological conditions. Here we report the discovery of a spirocyclic dimer (SpiD7) that covalently modifies RELA to inhibit TNF α -induced nuclear translocation. This is a previously unexplored strategy to inhibit TNF α -induced NF- κ B activation.

Induction of the canonical NF- κ B pathway activated by tumour necrosis factor (TNF) α , results in the nuclear translocation of RELA.¹ The presence of TNF α in the tumour microenvironment promotes constitutive activation of this pathway in ovarian and pancreatic tumours as well as other cancers.²⁻⁴ Several studies have shown that activation/inhibition of the pathway *via* genetic manipulation of the pathway proteins leads to either decreased/increased survival in mouse models of experimental cancer.⁵⁻¹⁰ Several strategies have been employed to develop therapeutic agents that block nuclear translocation of RELA. Therapeutics currently in clinical use include antibodies against TNF α , such as Humira[®], and small molecule inhibitors, such as Velcade[®]. In addition, we and others have reported an array of reversible and irreversible inhibitors that block the nuclear translocation of RELA and thus inhibit activation of RELA mediated transcription.¹¹⁻¹⁹

^a Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA. E-mail: anatarajan@unmc.edu

^b Mass Spectrometry and Proteomics Core Facility, University of Nebraska Medical Center, Omaha, NE 68198, USA

^c Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA

^d Structural Biochemistry Laboratory, Department of Chemistry & Biochemistry, San Diego State University, San Diego, CA 92182, USA

^e Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA

^f Department of Pharmaceutical Sciences and Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA

\dagger Electronic supplementary information (ESI) available. See DOI: [10.1039/d1cb00183c](https://doi.org/10.1039/d1cb00183c)

\ddagger Equal contribution.

\S Current address: SR (NIH/NCATS, MD).

The human RELA protein is 551 amino acids (aa) in length with a Rel homology region (RHR) containing an amino-terminal DNA recognition domain and a dimerization domain followed by a transcription activation domain (TAD) at the carboxy-terminal end.²⁰ In resting cells, RELA is retained in the cytoplasm by virtue of its binding to endogenous I κ B inhibitor proteins that mask the RELA nuclear localization signal (NLS).²¹ TNF α -induced activation of the pathway leads to the phosphorylation of I κ B α by the I κ B kinase (IKK) β subunit, resulting in the ubiquitination-dependent degradation of I κ B α thus allowing the nuclear translocation of RELA (Fig. S1, ESI \dagger).²²

There are 9 cysteine (Cys) residues in RELA and 6 (38, 95, 105, 109, 120, and 195) of the 9 Cys residues are solvent exposed (pdb id: 1IKN).²³ Surface exposed Cys residues that are not associated with catalytic or structural functions are less conserved and less abundant, thus making them attractive targets for precise modulation by covalent binders.²⁴ Recent reports show α -methylene- γ -butyrolactone containing natural product Helenalin analogues covalently target solvent exposed Cys residues 38 and 120 of RELA.^{25,26} Another α -methylene- γ -butyrolactone natural product, Parthenolide, was previously shown to covalently bind solvent exposed Cys 179 on IKK β .²⁷ Additionally, we previously showed that an isatin-derived α -methylene- γ -butyrolactone analogue **19**, covalently binds to both RELA and IKK β .¹⁶

The α -methylene- γ -butyrolactone moiety in the sesquiterpene natural products is fused to an alicyclic ring system. However, in analogue **19** the α -methylene- γ -butyrolactone moiety and the oxindole core form a spirocyclic system. Therefore, we hypothesized that the spirocyclic disposition of the α -methylene- γ -butyrolactone in analogue **19** could target different solvent exposed Cys residues in RELA and IKK β . To test this, we incubated recombinant RELA and IKK β with **19** or DMSO for 1 h on ice and the trypsinized samples were subjected to LC-MS/MS analyses (Fig. 1). Analyses of the tryptic digests revealed excellent coverage (>85%) in both treated and control samples. We identified 2 and 24 spectra in the






Fig. 1 Identification of **19** modified RELA and IKK β peptides. (A) Purified recombinant RELA or IKK β was incubated with **19** or DMSO and tandem mass spectrometry was performed on both trypsin and chymotrypsin digests of the protein to identify all RELA and IKK β peptides. Database searches with variable modification of cysteine residues that correspond to conjugation of **19** (+215 Da) were performed to identify modified peptides. (B) Graph of the total sequence coverage of RELA and IKK β accomplished by peptide mapping with mass spectrometry. (C) Analysis of the number of significant MS2 spectra with a Peptide Prophet probability $\geq 95\%$ mapping to RELA and IKK β with **19** modified sites. (D and E) Illustration of the mapping and abundance of **19** modified cysteine residues in RELA and IKK β . (F and G) Representative MS2 spectrum of a **19** modified peptide in RELA and IKK β . H. Protein Data Bank (PDB) structure of RELA (1IKN) and IKK β (4KIK) with **19**-modified cysteine residues indicated in red and the kinase domain of IKK β coloured cyan.

19-treated RELA and IKK β digests, respectively, that had a +215 Da adduct indicating covalent addition of **19** (Fig. S2, ESI ‡). Analyses of the MS2 spectra revealed that **19** covalently binds to Cys105 on RELA and Cys46, 299, 412 and 524 on IKK β . Docking studies using Schrödinger GLIDE identified basic amino acids proximal to each Cys residue that potentially increased the basicity of the sulphydryl groups, facilitating covalent C-S bond formation (Fig. S3, ESI ‡). Based on the docking score and assuming a two-step process (*i.e.*, binding followed by C-S bond formation) the pocket adjacent to Cys105 on RELA was deemed the most accessible, followed by the pocket adjacent to Cys412 on IKK β (Table S1, ESI ‡). Covalent modification of Cys105 and not Cys 38 on RELA by **19** is a novel finding, as Cys38 is the primary target of well characterized NF- κ B inhibitors, such as parthenolide and dehydroxymethyllepoxyquinomicin (DHMEQ). 28

Next, we assessed if **19** will covalently bind RELA and IKK β in cells using an alkyne-tagged **19**. Ovarian cancer cells (A2780) were subjected to alkyne-tagged **19**. Following a 1 h incubation the cells were pelleted, thoroughly washed and lysed. The lysates were subjected to click chemistry using biotin-azide and **19**-bound-biotin-tagged proteins in the lysates were pulled down using avidin beads following previously reported methods (Fig. 2). 15 Western blot analyses revealed the presence of RELA and IKK β in the pull down but not IKK γ or I κ B α despite the presence of solvent exposed Cys residues in the latter two proteins. Although limited to the proteins in the IKK complex this suggests that **19** selectively and covalently binds to RELA and IKK β in cells.





Fig. 2 Covalent binding of **19** to RELA and IKK β in cells. (A) Cancer cells (A2780) were incubated with 10 μ M of alkyne-tagged **19** for 1 h. The cells were thoroughly washed to remove unreacted **19** and lysed. The lysate was subjected to click reagents (TCEP, TBTA and CuSO₄) and azido-biotin. Biotin-tagged-**19**-bound proteins were subjected to mono-avidin column. Biotin-tagged proteins were captured, the column was washed to remove untagged proteins and the biotin-tagged-**19**-bound proteins were eluted with regeneration buffer (6 M urea/PBS). (B) The eluted lysates were subjected to western blot analyses and probed for proteins (IKK β , RELA, I κ B α and I κ K γ) in the IKK complex. Cys residues for the protein in the IKK complex that bound to **19** *in vitro* are shown in red and the solvent exposed Cys residues are shown in blue.

Since RELA and IKK β are part of an ~ 900 kDa protein complex, 29,30 we rather naively speculated that a dimer of **19** could crosslink RELA and/or IKK β to their binding partners, which is a previously unexplored modality for targeting the IKK complex. We synthesized a dimer of isatin (**1**), by alkylating the ends of 1,7-dibromoheptane in the presence of NaH. The isatin-dimer **1** was subjected to an indium catalysed Barbier-type reaction to set up the carbon framework for the spirocyclic core structure. 31 An acid catalysed ring closure of the acyclic compound **2** yielded the desired spirocyclic dimer **7** (SpiD7) (Scheme 1). Iodoacetamide is commonly used in mass spectrometry to alkylate Cys residues. To examine the role of the isatin-derived spirocyclic core, we also synthesized an iodoacetamide dimer analogue SpiD7-C (Scheme 1). The distance between the active methylene groups in SpiD7-C is ~ 16 \AA , which is similar to the distance between the Michael acceptors in SpiD7 (blue arrow, Scheme 1).



Scheme 1 Synthesis of spirocyclic dimer **7** (SpiD7) and a control iodoacetamide dimer compound (SpiD7-C) where the electrophilic carbon atoms (blue arrows) are ~ 16 \AA apart. Reaction conditions: (i) 1,7-Dibromoalkane, NaH, DMF, RT, 16 h, 80%; (ii) Methyl 2-(bromomethyl)acrylate, In, THF: water, RT, 24 h, 75%; (iii) TsOH, DCM, RT, 24 h, 80%; (iv) 2-chloroacetyl chloride, K₂CO₃, DCM; (v) NaI, acetone, reflux, 24 h.






Fig. 3 *In vitro* and cellular crosslinking studies with SpiD7, **19** and SpiD7-C. (A) Equimolar concentrations (7.72 μ M) of the reactants were mixed and incubated for 24 h at 4 °C. Following incubation, the mixture was subjected to SDS-PAGE and the gel subjected to silver staining. (B) WB analysis of the *in vitro* reactions. Red arrows indicate the HMW protein cross-link bands. (C) Cancer cells (A2780 and OVCAR5) were treated with and without **19**, SpiD7 and SpiD7-C (10 μ M) for 2 h. The lysates were subjected to WB analyses with antibodies against the indicated proteins. (D) OVCAR5 cells were incubated with 10 μ M of either **19** or SpiD7 for 2 h (lanes 1–3). In parallel, cells were treated with increasing concentration of **19** (1–50 μ M) followed by 10 μ M of SpiD7 (lanes 4–7). Following a 2 h incubation lysates from the above, treatments were probed with RELA and α -tubulin antibodies.

Next, to determine if the dimers crosslink proteins we set up *in vitro* reactions with recombinant RELA and IKK β in the presence and absence of **19**, SpiD7 or SpiD7-C (Fig. 3A and B). The reactions were analysed *via* SDS-PAGE and visualised either by silver staining or by membrane transfer and immunodetection by western blot (WB) with anti-His antibody to detect his-tagged recombinant IKK β and anti-RELA antibody. When compared to RELA and IKK β alone lanes, we observed additional high molecular weight (MW) bands present only in the SpiD7-treated lane but not in **19**- or SpiD7-C-treated lanes. Also, we observed a modest reduction of RELA and IKK β levels in the SpiD7-treated lane, but not in the controls. Moreover, the banding pattern in **19**- and SpiD7-C-treated lanes was similar to that of RELA and IKK β alone lanes.

To determine if the *in vitro* observation translates to a cellular system, we subjected cancer cells to either DMSO, **19**, SpiD7 or SpiD7-C and probed the lysates for RELA. In both cell lines tested, SpiD7 showed three distinct high MW bands (\sim 105, 130 and 230 kDa) while no such high MW bands were observed in **19** or SpiD7-C-treated cells indicating that dimerization and the spiroisatin core are required for crosslinking RELA to its binding partners (Fig. 3C). We did not observe any high MW bands when we probed for IKK β (data not shown). To determine if dimer (SpiD7) and monomer **19** bind to the same proteins, we conducted a competition assay. Cells were treated with increasing concentrations (1–50 μ M) of **19**, followed by 10 μ M of SpiD7, and incubated for 2 h. Western blot analyses of the lysates showed a dose-dependent decrease in the high MW bands (lanes 4–7, Fig. 3D). This demonstrates that monomer **19** and dimer SpiD7 bind to the same sites on RELA and the high MW bands (\sim 105, 130 and 230 kDa) are a direct result of the dimerization of **19**.




Fig. 4 Functional consequence of RELA stapling by SpiD7 (A) Cancer cells (OVCAR5) were treated with and without **19** or SpiD7 (10 μ M) and either stimulated with TNF α (20 ng mL^{-1}) for 15 min or held as control. Cytoplasmic and nuclear cell fractions were subjected to WB analyses using antibodies for the indicated proteins. (B) Dose–response study with SpiD7 to assess inhibition of TNF α -induced RELA activation in a dual luciferase reporter assay. (C) OVCAR5 cells treated with either DMSO or SpiD7 (10 μ M) and stimulated by TNF α (20 ng mL^{-1}) for 30 min or 180 min. Gene Set Enrichment Analysis (GSEA) for the Hallmark TNF α _signaling_via_NF- κ B (200) gene set. Euclidean hierarchical clustering of the log2-fold change of genes, where at least one of the treatment comparisons was significantly different (FDR adjusted p -value < 0.05).

To determine the functional consequence of SpiD7-induced RELA crosslinking (stapling), we subjected two sets of cancer cells to either DMSO, **19** or SpiD7. One set of cells were then stimulated with TNF α while the other served as the control. Following a 15 min incubation, the lysates were fractionated and the cytoplasmic and nuclear fractions of all the treated and control samples were subjected to WB analyses (Fig. 4). Consistent with the above studies we observed high MW RELA bands only in the cytoplasmic fraction of the SpiD7-treated lanes. Consistent with *in vitro* studies we observed a reduction in the IKK β levels in the SpiD7-treated cells. As expected in the control lanes (1 and 4) of the cytoplasmic fraction, TNF α stimulation resulted in reduced I κ B α levels due to ubiquitination-dependent degradation. This reduction was modestly inhibited in **19**-treated cells, while it was completely blocked in the SpiD7-treated cells (lanes 4–6, Fig. 4A). Conversely, as expected, in the control lanes (7 and 10) of the nuclear fraction TNF α stimulation resulted in increased levels of RELA. This increase was modestly diminished in **19**-treated cells and completely lost (compare unstimulated control lane 7 and lane 12) in the SpiD7-treated cells (lanes 10–12, Fig. 4A). Together these data show that stapling RELA to its binding partners by SpiD7 resulted in potent inhibition of TNF α -induced RELA translocation. Consistent with this observation, SpiD7 inhibited TNF α -induced RELA activity in a luciferase reporter assay in a dose-dependent manner (Fig. 4B).

We conducted RNA-seq studies to assess the changes in RNA levels upon TNF α stimulation in the presence and absence of SpiD7. OVCAR5 cells were treated with SpiD7 for 2 h and

stimulated with TNF α for 30 min or 180 min. Isolated RNA from these samples were subjected to RNA-seq analysis (Fig. 4C). Gene set enrichment analysis (GSEA) for Hallmark_TNF α -signaling_via_NFKB yielded normalized enrichment scores (NES) of +2.89 and +3.14 for the TNF α stimulated samples, while the SpiD7 treatment followed by TNF α stimulation yielded -2.30 and -2.24 NES. The heat map provides an unbiased view of changes wherein one or more of the treatments resulted in a significant difference. Representative genes that are known to be regulated by TNF α stimulation at 30 min and 180 min, are NFKBIA (IkB α) and NFKB1 (p105), respectively.³² As expected, TNF α induced NFKBIA (IkB α) expression is inhibited by SpiD7 at the 30 min time point (compare lanes 1 and 3 of the heat map) and NFKB1 which is elevated at the 180 min timepoint, is inhibited by SpiD7 (compare lanes 2 and 4 of the heatmap). Together these data strongly suggest that SpiD7 inhibits TNF α -induced NF- κ B transcription. We conducted a growth inhibition assay with OVCAR8 cells to determine the relative potency of SpiD7 and Analog **19** (Fig. S4, ESI †). The results showed that SpiD7 was \sim 15-fold more potent than **19**. We also show that SpiD7 selectively induced Caspase-7 and PARP cleavage in OVCAR5 but not in FTE282C11 cells (Fig. S5, ESI †).

In conclusion, here we report the Cys residues on RELA and IKK β targeted by the α -methylene- γ -butyrolactone-containing spirocyclic compound **19**. The spirocyclic architecture allows targeting Cys residues that are not accessible to the fused α -methylene- γ -butyrolactone-containing sesquiterpene natural products or their analogues. We also show that SpiD7, a dimer of **19**, staples RELA to its binding partners to yield stable high MW bands. Characterization of the stable high MW bands are currently underway and will be reported in due course. More importantly, SpiD7 inhibits TNF α -induced nuclear translocation of RELA resulting in the blockade of NF- κ B gene transcription, through a previously unexplored modality.

Conflicts of interest

A. N. and S. R. are listed as inventors on US patent 11 104 684.

Acknowledgements

This work was supported in part by NIH grants CA197999, CA127297 and CA036727. S. Ko was supported by a predoctoral UNMC fellowship. Research resources at UNMC are supported in part by the Nebraska Research Initiative. Biochemistry research at SDSU is supported in part by the California Metabolic Research Foundation. We would like to thank the Natarajan lab members for helpful discussions.

References

- 1 M. S. Hayden and S. Ghosh, *Cell*, 2008, **132**, 344–362.
- 2 D. F. Lee, H. P. Kuo, C. T. Chen, J. M. Hsu, C. K. Chou, Y. Wei, H. L. Sun, L. Y. Li, B. Ping, W. C. Huang, X. He, J. Y. Hung, C. C. Lai, Q. Ding, J. L. Su, J. Y. Yang, A. A. Sahin, G. N. Hortobagyi, F. J. Tsai, C. H. Tsai and M. C. Hung, *Cell*, 2007, **130**, 440–455.
- 3 B. S. Harrington and C. M. Annunziata, *Cancers*, 2019, **11**, 1182.
- 4 W. Wang, J. L. Abbruzzese, D. B. Evans, L. Larry, K. R. Cleary and P. J. Chiao, *Clin. Cancer Res.*, 1999, **5**, 119–127.
- 5 K. Vlantis, A. Wullaert, Y. Sasaki, M. Schmidt-Supplian, K. Rajewsky, T. Roskams and M. Pasparakis, *J. Clin. Invest.*, 2011, **121**, 2781–2793.
- 6 E. Maniati, M. Bossard, N. Cook, J. B. Candido, N. Emami-Shahri, S. A. Nedospasov, F. R. Balkwill, D. A. Tuveson and T. Hagemann, *J. Clin. Invest.*, 2011, **121**, 4685–4699.
- 7 H. Shaked, L. J. Hofseth, A. Chumanevich, A. A. Chumanevich, J. Wang, Y. Wang, K. Taniguchi, M. Guma, S. Shenouda, H. Clevers, C. C. Harris and M. Karin, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 14007–14012.
- 8 J. Ling, Y. Kang, R. Zhao, Q. Xia, D. F. Lee, Z. Chang, J. Li, B. Peng, J. B. Fleming, H. Wang, J. Liu, I. R. Lemischka, M. C. Hung and P. J. Chiao, *Cancer Cell*, 2012, **21**, 105–120.
- 9 Y. Xia, N. Yeddula, M. Leblanc, E. Ke, Y. Zhang, E. Oldfield, R. J. Shaw and I. M. Verma, *Nat. Cell Biol.*, 2012, **14**, 257–265.
- 10 M. Naramura and A. Natarajan, *Pancreas*, 2018, **47**, e27–e29.
- 11 J. A. Prescott and S. J. Cook, *Cells*, 2018, **7**, 115.
- 12 M. Suhail, M. Tarique, N. Muhammad, H. Naz, A. Hafeez, T. A. Zughabi, M. A. Kamal and M. Rehan, *Curr. Med. Chem.*, 2021, **28**, 4117–4132.
- 13 T. D. Gilmore and M. Herscovitch, *Oncogene*, 2006, **25**, 6887–6899.
- 14 S. Sagar, S. Singh, J. R. Mallareddy, Y. A. Sonawane, J. V. Napoleon, S. Rana, J. I. Contreras, C. Rajesh, E. L. Ezell, S. Kizhake, J. C. Garrison, P. Radhakrishnan and A. Natarajan, *Eur. J. Med. Chem.*, 2021, **222**, 113579.
- 15 S. Rana, S. Kour, Y. A. Sonawane, C. M. Robb, J. I. Contreras, S. Kizhake, M. Zahid, A. R. Karpf and A. Natarajan, *Chem. Biol. Drug Des.*, 2020, **96**, 773–784.
- 16 S. Rana, E. C. Blowers, C. Tebbe, J. I. Contreras, P. Radhakrishnan, S. Kizhake, T. Zhou, R. N. Rajule, J. L. Arnst, A. R. Munkarah, R. Rattan and A. Natarajan, *J. Med. Chem.*, 2016, **59**, 5121–5127.
- 17 P. Radhakrishnan, V. C. Bryant, E. C. Blowers, R. N. Rajule, N. Gautam, M. M. Anwar, A. M. Mohr, P. M. Grandgenett, S. K. Bunt, J. L. Arnst, S. M. Lele, Y. Alnouti, M. A. Hollingsworth and A. Natarajan, *Clin. Cancer Res.*, 2013, **19**, 2025–2035.
- 18 V. C. Bryant, G. D. Kishore Kumar, A. M. Nyong and A. Natarajan, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 245–248.
- 19 J. V. Napoleon, S. Singh, S. Rana, M. Bendjennat, V. Kumar, S. Kizhake, N. Y. Palermo, M. M. Ouellette, T. Huxford and A. Natarajan, *Chem. Commun.*, 2021, **57**, 4678–4681.
- 20 T. Huxford and G. Ghosh, *Cold Spring Harbor Perspect. Biol.*, 2009, **1**, a000075.
- 21 S. Malek, Y. Chen, T. Huxford and G. Ghosh, *J. Biol. Chem.*, 2001, **276**, 45225–45235.
- 22 F. Liu, Y. Xia, A. S. Parker and I. M. Verma, *Immunol. Rev.*, 2012, **246**, 239–253.
- 23 T. Huxford, D. B. Huang, S. Malek and G. Ghosh, *Cell*, 1998, **95**, 759–770.



24 S. M. Marino and V. N. Gladyshev, *J. Mol. Biol.*, 2010, **404**, 902–916.

25 J. C. Widen, A. M. Kempema, J. W. Baur, H. M. Skopec, J. T. Edwards, T. J. Brown, D. A. Brown, F. A. Meece and D. A. Harki, *ChemMedChem*, 2018, **13**, 303–311.

26 J. C. Widen, A. M. Kempema, P. W. Villalta and D. A. Harki, *ACS Chem. Biol.*, 2017, **12**, 102–113.

27 B. H. Kwok, B. Koh, M. I. Ndubuisi, M. Elofsson and C. M. Crews, *Chem. Biol.*, 2001, **8**, 759–766.

28 M. Yamamoto, R. Horie, M. Takeiri, I. Kozawa and K. Umezawa, *J. Med. Chem.*, 2008, **51**, 5780–5788.

29 E. Zandi, D. M. Rothwarf, M. Delhase, M. Hayakawa and M. Karin, *Cell*, 1997, **91**, 243–252.

30 G. Chen, P. Cao and D. V. Goeddel, *Mol. Cell*, 2002, **9**, 401–410.

31 S. Rana and A. Natarajan, *Org. Biomol. Chem.*, 2013, **11**, 244–247.

32 B. Tian, D. E. Nowak and A. R. Brasier, *BMC Genomics*, 2005, **6**, 137.

